Equity reseach Pila Pharma: Sizing up a small molecule in obesity

Read the full report here:

Pila Pharma is developing its lead candidate, XEN-D0501, a TRPV-1 antagonist in metabolic disease, with potential applications in pain and other inflammatory indications, such as Erythromelalgia (EM). With a candidate dosed in 300 humans, PILA appears to have a unique TRPV1 antagonist profile, safety-wise. The data provide a rationale for investigating higher oral dosing in the planned Phase Ib/IIa trials for the piping-hot obesity indication.

Clinical stage research company punching above its weight

Pila Pharma is developing XEN-D0501, a potential first-in-class oral treatment that is a selective small molecule TRPV1 antagonist (also known as the “chilli or capsaicin receptor”). This mechanism is known to regulate neurogenic inflammation, a key factor in many diseases. The candidate has demonstrated enhanced endogenous insulin response in Phase 2a trials in overweight people with type 2 diabetes. The company’s focus is now to expand the data package by assessing XEN-D0501 in obesity. Injectable peptide solutions have established a multi-billion-dollar market. After injectable single GLP-1 agonists and the dual agonist tirzepatide, orals are the next emerging segment in obesity drugs. Recent launches by Novo Nordisk and Eli Lilly in 2026 indicate strong demand for obesity pills.

Broad effect enables secondary indications

Given that the target, TRPV1, is a key regulator of inflammation and pain, the company’s candidate is expected to have several applications. The FDA, for example, granted Pila Pharma Orphan drug designation for Erythromelalgia in July 2022, a rare and painful autoimmune disease. Currently, no targeted therapies are approved, suggesting that XEN-D0501 could be a first-in-class treatment. Due to its small-molecule nature, Pila Pharma could, in addition to its currently developed tablet formulation, explore a dermal/topical formulation to better align with patient needs. With a perceived potent direct anti-inflammatory effect, the application possibilities also include cardiovascular conditions, skin conditions, and other inflammatory diseases.

Preparing to restart clinical development

We believe Pila Pharma’s valuation reflects sluggish sentiment toward early-stage Nordic biotech companies. Also, the preclinical obesity studies initiated in 2025 could not be conducted with the intended formulation, and the results were inconclusive, creating some uncertainty. As a result, the subscription rate in the TO2 warrant program was low. We see a clear road to higher valuation when PILA restarts its clinical development with a primary focus on obesity. Currently, the company is preparing a CTA (clinical trial application) suggesting a trial start in 6-12 months, in our view.  Our base-case valuation is SEK 2.5 per share, after expected financing for planned clinical development.  We view the bet on obesity as high risk/high reward; however, secondary indications provide some downside protection if obesity trials do not pan out.

Disclaimer

Carlsquare AB. www.carlsquare.se, hereafter referred to as Carlsquare, conducts operations in Corporate Finance and Equity Research and thereby publishes information about companies, including analyses. The information has been compiled from sources that Carlsquare considers reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or similar. Opinions and conclusions expressed in the analysis are intended solely for the recipient.

The content may not be copied, reproduced, or distributed to any other person without the written consent of Carlsquare. Carlsquare shall not be liable for any direct or indirect damage caused by decisions made based on information contained in this analysis. Investments in financial instruments provide opportunities for capital appreciation and profits. All such investments are also associated with risks. The risks vary between different types of financial instruments and combinations thereof. Historical returns should not be considered as an indication of future returns.

The research is not directed at U.S. Persons (as that term is defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Companies Act 1940) and may not be distributed to such persons. Nor is the analysis aimed at such natural or legal persons where the distribution of the analysis to such persons would involve or entail a risk of violation of Swedish or foreign law or regulations.

The analysis is a so-called commissioned analysis where the analysed company has signed an agreement with Carlsquare for analysis coverage. The analyses are published continuously during the contract period and against customary fixed remuneration.

Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values ensuring objectivity and independence and has therefore established procedures for managing conflicts of interest.

The analysts Niklas Elmhammer and Herman Kuntscher do not and may not own shares in the analysed company.